MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, BBOT has $417,646K in assets. $45,366K in debts. $52,658K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
616.05%
Quick Ratio
616.05%
Cash Ratio
121.72%
Debt to Asset Ratio
10.86%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term marketable securities
    • Long-term marketable securities
    • Cash and cash equivalents
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued research and development...
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
52,658 373,687 408,741
Short-term marketable securities
199,617 51,773 59,544
Receivables from related parties
146 386 226
Prepaid expense and other current assets
14,081 6,550 7,499
Total current assets
266,502 432,396 476,010
Long-term marketable securities
136,617 --
Property and equipment, net
938 956 827
Operating lease right-of-use asset
2,218 2,330 2,440
Other non-current assets
11,239 12,567 5,384
Restricted cash
132 132 132
Total assets
417,646 448,381 484,793
Accounts payable
12,090 1,374 3,650
Accrued compensation and benefits
2,018 5,746 4,489
Accrued research and development liabilities
25,920 25,951 24,107
Accrued professional services
1,433 674 2,091
Payables to related parties
716 534 691
Operating lease liability, current
538 522 506
Other accrued liabilities
545 240 178
Participation right liability
-0 0
Total current liabilities
43,260 35,041 35,712
Operating lease liability, noncurrent
2,106 2,244 2,381
Total liabilities
45,366 37,285 38,093
Preference stock, value-Redeemable Convertible Preferred Stock
0 0 0
Preference stock, value-Preferred Stock
0 0 0
Common stock, 0.0001 par value 500,000,000 shares authorized as of march 31, 2026 and december 31, 2025, respectively 80,088,931 and 79,991,768 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively
8 8 8
Additional paid-in capital
771,926 767,639 764,426
Accumulated deficit
-398,673 -356,567 -317,770
Accumulated other comprehensive income
-981 16 36
Total stockholders' equity
372,280 411,096 446,700
Total liabilities, redeemable convertible preferred stock, and stockholders' equity
417,646 448,381 484,793
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term marketablesecurities$199,617K Cash and cashequivalents$52,658K Prepaid expense andother current assets$14,081K Receivables from relatedparties$146K Total current assets$266,502K Long-term marketablesecurities$136,617K Other non-currentassets$11,239K Operating leaseright-of-use asset$2,218K Property and equipment,net$938K Restricted cash$132K Total assets$417,646K Total liabilities,redeemable convertible...$417,646K Total stockholders'equity$372,280K Total liabilities$45,366K Accumulated deficit-$398,673K Accumulated othercomprehensive income-$981K Additional paid-in capital$771,926K Total currentliabilities$43,260K Operating leaseliability, noncurrent$2,106K Common stock, 0.0001par value...$8K Accrued research anddevelopment liabilities$25,920K Accounts payable$12,090K Accrued compensationand benefits$2,018K Accrued professionalservices$1,433K Payables to relatedparties$716K Other accruedliabilities$545K Operating leaseliability, current$538K

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics, Inc. (BBOT)